Streetbeat News

SCNI

Scinai Immunotherapeutics Ltd.

https://www.scinai.com

Industry

Biotechnology

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Open

2.75

Mkt cap

2.5M

Volume

15K

High

2.95

P/E Ratio

-0.37

52-wk high

8.92

Low

2.73

Div yield

N/A

52-wk low

2.23

Scinai Immunotherapeutics shares rose after the company announced it regained compliance with Nasdaq listing requirements.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:43 pm

Scinai Immunotherapeutics has regained compliance with Nasdaq's listing rule by maintaining a stockholders' equity of at least $2.5 million.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 10:33 am

Scinai Immunotherapeutics has entered into a $2 million investment commitment agreement with RK Stone Miami. This agreement allows Scinai to sell American Depositary Shares (ADS) at its discretion through December 2024.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:31 pm

Scinai Immunotherapeutics has signed a definitive loan restructuring agreement with the European Investment Bank, converting approximately $29 million of debt into preferred equity, which is convertible into 19.5% equity.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:14 am

ASLAN Pharmaceuticals shares dropped over 38% after announcing the voluntary liquidation of its sole operating subsidiary. Other notable stock movements include Aptevo Therapeutics climbing 84% following a $2.75 million offering, and Shimmick Corporation rising 49% after securing a $27.6 million subcontract. Cassava Sciences fell nearly 30% due to executive leadership changes.

Portfolio Pulse from Avi Kapoor

July 17, 2024 | 5:28 pm

U.S. stocks traded higher with the Dow Jones rising over 150 points. Goldman Sachs reported better-than-expected Q2 results, boosting its stock. Energy shares jumped 2%, while utilities fell 1.8%. Notable stock movements include SCNI, AMIX, DJT, ASLN, VTAK, and LXEO.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 6:32 pm

SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares fell 12.2% after announcing a workforce reduction of 400 employees. Other notable stock movements include Autonomix Medical, Inc. (NASDAQ:AMIX) climbing 148% and Trump Media & Technology Group Corp. (NASDAQ:DJT) rising 32.8% following an attempted assassination of Donald Trump.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 5:23 pm

U.S. stocks traded higher with the Nasdaq Composite rising over 1%. Key movers included Scinai Immunotherapeutics, Autonomix Medical, and Trump Media & Technology Group, which saw significant gains. Lexeo Therapeutics, ASLAN Pharmaceuticals, and Catheter Precision experienced notable declines.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 4:05 pm

Scinai Immunotherapeutics shares have resumed trading.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:48 pm

U.S. stocks traded higher on Monday with the Dow Jones gaining over 200 points. The NY Empire State Manufacturing Index fell to -6.6 in July. Notable stock movements include Scinai Immunotherapeutics, DatChat, and MIRA Pharmaceuticals rising significantly, while ASLAN Pharmaceuticals, Qualigen Therapeutics, and Lexeo Therapeutics saw substantial declines.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 1:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.